• ABPI Website
  • Media
  • ABPI response to 'Healthy Mum, Healthy Baby, Healthy Future' report
ABPI response to 'Healthy Mum, Healthy Baby, Healthy Future' report

The 'Healthy Mum, Healthy Baby, Healthy Future' report from the University of Birmingham sets out the case for developing more medicines for use in pregnancy. 

Pharmaceutical companies are already working as part of global research initiatives to generate reliable evidence on medicines used during pregnancy. Steve Hoare, ABPI Director of Quality, Regulatory Science and Safety Policy

In response, Steve Hoare, the ABPI's Director of Quality, Regulatory Science & Safety Policy, said: 

“It’s clear that much more needs to be done to improve the treatment options available to pregnant women.

“Pharmaceutical companies are already working as part of global research initiatives to generate reliable evidence on medicines used during pregnancy.

"As part of this, we are committed to working with Government, regulators and the wider life sciences sector to put the constructive solutions of this report into practice.”

Read the report at Birmingham Health Partners
TAGS
  • Clinical research

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.